Hypertriglyceridemia Clinical Trial
— EVAPORATEOfficial title:
Effect of Vascepa on Progression of Coronary Atherosclerosis in Persons With Elevated Triglycerides (200-499) on Statin Therapy
Effect of Vascepa on Progression of Coronary Atherosclerosis in Persons with Elevated Triglycerides (200-499) on Statin Therapy. The study is to determine progression rates of low attenuation plaque under influence of Vascepa as compared to placebo.
Status | Completed |
Enrollment | 80 |
Est. completion date | August 15, 2020 |
Est. primary completion date | May 15, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 30 Years to 85 Years |
Eligibility | Inclusion Criteria: - Elevated triglycerides (fasting value between 200-499 mg/dl) at qualifying or baseline visit. - LDL-C =115 mg/dL on appropriate statin therapy - LDL-C >40 mg/dL - Stable diet and exercise, as defined as the same pattern for the previous 4 weeks - Stable treatment with a statin+/- ezetimibe for at least 4 weeks - Patients with at least 1 angiographic stenosis with at least 20% narrowing by coronary computed tomography angiography (CTA). - Willingness to be on birth control for women of childbearing age or established post-menopausal Exclusion Criteria: - A contraindication to fish or fish oils including: known hypersensitivity to drug or fish. - Any unstable medical, psychiatric or substance abuse disorder that in the opinion of the investigator or principal investigator is likely to affect the subject's ability to complete the study or precludes the subject's participation in the study. - Non-study lipid altering medications or supplements (ie - Niacin, PCSK9, fibrates, bile acid Sequestrants, dietary fish oil supplement capsules, orlistat [OTC (Alli®) as well as Rx (Xenical®)] or other drugs used for weight loss). - Stable (same daily dose for the last 4 weeks) on medications that can affect lipids (retinoids, hormones, steroids, HIV medications, chemotherapy, thyroid medications). - BMI > 40 - Bleeding disorder - Uncontrolled hypertension (SBP= 180 mmHg or DBP=100 mmHg) - History of known myocardial infarction, stroke or life-threatening arrhythmia within the prior six months. - NYHA Class III- IV heart failure - History of malignancy within the last 5 years (other than skin cancer) or evidence of active cancer which would require concomitant cancer chemotherapy. - Serum creatinine > 1.4 mg/dl - Drug or alcohol abuse, or current intake of more than 14 ounces of alcohol per week for men and 10 ounces for women - Concurrent enrollment in another placebo-controlled trial or within 30 days of finishing another trial - Partial ileal bypass or known gastrointestinal disease limiting drug absorption - History of hypertensive encephalopathy or cerebrovascular accident - Hematological or biochemical values at screening outside the reference ranges considered as clinically significant in the opinion of the investigator or PI - Pregnancy - Genetic mutations/polymorphisms having an effect on blood lipids - History of coronary artery bypass surgery - Allergy to contrast material - Allergy to beta-blocker in subjects with resting heart rate >70 bpm |
Country | Name | City | State |
---|---|---|---|
United States | Intermountain Medical Center, Intermountain Heart Institute | Murray | Utah |
United States | Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center (The Lundquist Institute) | Torrance | California |
Lead Sponsor | Collaborator |
---|---|
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Intermountain Research and Medical Foundation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression Rates of Low Attenuation Plaque Under Influence of Vascepa as Compared to Placebo as a Change Between Two or More Time Points | low attenuation plaque volume change from baseline to 18 months | 18 months | |
Secondary | The Composition of Non-calcified Coronary Atherosclerotic Plaque (NCP) | the measure is reported as volume of non-calcified plaque, as the secondary measure has been reported. | 18 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03929198 -
Translation of Pritikin Program to the Community
|
N/A | |
Completed |
NCT02250105 -
Trial of ARI-3037MO to Reduce Triglyceride Levels in Adults With Severe (≥500 mg/dl) Hypertriglyceridemia
|
Phase 2 | |
Completed |
NCT02859129 -
Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)
|
Phase 1 | |
Completed |
NCT01455844 -
TRIal For Efficacy of Capre on hyperTriglyceridemiA
|
Phase 2 | |
Completed |
NCT01437930 -
Intervention With n-3 Polyunsaturated Fatty Acids (PUFA)-Supplemented Products in Moderate Hypertriglyceridemic Patients
|
N/A | |
Completed |
NCT01010399 -
Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects
|
Phase 4 | |
Completed |
NCT00959842 -
Effects of Lovaza on Lipoprotein Composition and Function in Mild Hypertriglyceridemia
|
Phase 1/Phase 2 | |
Completed |
NCT00519714 -
A Study to Evaluate the Lipid Regulating Effects of 1-Methylnicotinamide (1-MNA)
|
Phase 2/Phase 3 | |
Recruiting |
NCT00186537 -
Comparing Tricor, Avandia, or Weight Loss to Lower Cardiovascular Risk Factors in People With High Triglycerides.
|
N/A | |
Completed |
NCT00246402 -
Acipimox to Improve Hyperlipidemia and Insulin Sensitivity Associated With HIV
|
N/A | |
Completed |
NCT06020950 -
Chia Seeds Consumption in Hypertriglyceridemia
|
N/A | |
Completed |
NCT02354976 -
A Double-blind Randomized Placebo-controlled Study Comparing Epanova and Fenofibrate on Liver Fat in Overweight Subjects.
|
Phase 2 | |
Completed |
NCT04966494 -
Impact of Beans and Oats Snack Bar on Hypertriglyceridemic Women
|
N/A | |
Completed |
NCT04630366 -
A Phase 1, First Time in Humans Study of NST-1024
|
Phase 1 | |
Completed |
NCT04650152 -
Study to Assess Tricor Therapy Effectiveness in Patients With Metabolic Syndrome (TRISTAN)
|
||
Completed |
NCT03693131 -
Efficacy of MND-2119 in Participants With Hypertriglyceridemia
|
Phase 3 | |
Completed |
NCT02868177 -
Effect of Totum-63, Active Ingredient of Valedia, on Glucose and Lipid Homeostasis on Subjects With Prediabetes
|
Phase 2/Phase 3 | |
Completed |
NCT04756180 -
An Efficacy and Safety Study of Omega-3-acid Ethyl Ester in Chinese Subjects With Hypertriglyceridemia.
|
Phase 3 | |
Completed |
NCT01968720 -
Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia
|
Phase 2 | |
Completed |
NCT01462877 -
A Study to Evaluate Fenofibrate Combination With Statin in Chinese Patients With Dyslipidemic
|
Phase 4 |